News
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
19h
Zacks Investment Research on MSNNovo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...
11h
Stockhead on MSNBig pharma takes notice as Novo Nordisk puts Clever Culture’s APAS to the testClever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a ... Read More ...
Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...
Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working ...
Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...
Explore more
Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...
Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
Novo Nordisk today announced a collaboration with the American Society of Haematology (ASH) to support the Consortium on Newborn Screening in Africa (CONSA) Community Health Worker (CHW) Initiative.
The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...
The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results